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Evidence indicates that the growth of glioblastoma (GBM), the most common and malignant primary
brain cancer, is driven by glioma stem cells (GSCs) resistant to current treatment. As Wnt-signaling is
pivotal in stem cell maintenance, we wanted to explore its role in GSCs with the objective of ﬁnding
distinct signaling mechanisms that could serve as potential therapeutic targets. We compared gene
expression in GSCs (n¼9) and neural stem cells from the adult human brain (ahNSC; n¼3) to identify
dysregulated genes in the Wnt signaling pathway. This identiﬁed a six-gene Wnt signature present in all
nine primary GSC cultures, and the combined expression of three of these genes (SFRP1, SFRP4 and FZD7)
reduced median survival of glioma patients from 38 to 17 months. Treatment with recombinant SFRP1
protein in primary cell cultures downregulated nuclear β-catenin and decreased in vitro proliferation and
sphere formation in a dose-dependent manner. Furthermore, expressional and functional analysis of
SFRP1-treated GSCs revealed that SFRP1 halts cell cycling and induces apoptosis. These observations
demonstrate that Wnt signaling is dysregulated in GSC, and that inhibition of the Wnt pathway could
serve as a therapeutic strategy in the treatment of GBM.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glioblastoma (GBM) is the most common and malignant pri-
mary brain tumor in humans. The tumor invariably recurs despite
aggressive treatment, including surgery, irradiation and che-
motherapy. Median survival is therefore less than one year in
unselected patient populations. GBMs contain glioma stem cells
(GSCs) that have a phenotype similar to adult human neural stem
cells (ahNSCs) [1]. These cells are drivers of GBM propagation [2,3]
and therapy resistance [4], and are thus believed to be responsible
for the invariable recurrence of the tumor.
When cultured under serum-free, growth factor-enriched
conditions, both ahNSCs and GSCs grow in spherical aggregates of
cells known as neuro- or tumorspheres. Such spheres may be
differentiated into the different lineages of the central nervous
system [1,5]. The ability to form spheres has been shown to be anInc. This is an open access article u
l; GSC, glioma stem cell
stitute for Surgical Research,
4 Oslo, Norway.independent predictor of clinical outcome [6,7]. When trans-
planted to rodents, GSCs give rise to rapidly growing invasive tu-
mors that resemble their tumor of origin [2].
The Wnt signaling system is a set of highly conserved pathways
required for stemness and self-renewal in both embryonic and
adult stem cells [8]. In Wnt/β-catenin signaling, β-catenin is
phosphorylated by the β-catenin destruction complex (consisting
of glycogen synthase kinase 3β (GSK3β), adenomatosis polyposis
coli (APC), Axin and casein kinase 1 (CKI)) in the absence of Wnt
activation. Phosphorylation at the N-terminal marks β-catenin for
ubiquitination and degradation by the proteasome, thus keeping
its levels low [9]. In humans, Wnt/β-catenin signaling is initiated
when a Wnt ligand (19 in total) binds to the surface receptors
Frizzled (Fzd; 10 in total) in the presence of the co-receptor low-
density-lipoprotein-related protein 5/6 (LRP5/6). This induces
phosphorylation of dishevelled (DVL), leading to the recruitment
of the destruction complex to the Wnt-receptor complex, where it
is inactivated. In the absence of the destruction complex unpho-
sphorylated, active β-catenin accumulates and translocates to the
nucleus where it activates transcription of target genes with thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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enhancer factor (LEF) and their co-factors [10,11]. Wnt/β-catenin
typically induces the transcription of genes involved in differ-
entiation, proliferation and resistance to apoptosis [12,13].
Wnt signaling is modiﬁed by a number of antagonists, includ-
ing the family of soluble Frizzled-related proteins (SFRPs). These
are extracellular proteins that can bind either to the extracellular
domain of Fzd receptors or directly to Wnts. They generally act as
Wnt-inhibitors, although they also may enhance Wnt-signaling
under special circumstances [14]. SFRP1, the most extensively
characterized family member, is a well-established tumor-sup-
pressor, and epigenetic silencing of SFRP1 occurs in a number of
malignancies [15], including gliomas [16].
Aberrant Wnt-signaling is thought to be essential for cancer
stem cells (CSCs) of various origins, including bladder, blood,
breast, colon, and skin [8], where it regulates diverse processes
involved in stem cell maintenance [8] and therapy resistance
[17,18]. Unlike a number of other cancers, mutations in the Wnt
pathway that result in constitutively active signaling are in-
frequent in GBM. Even so we recently found that Wnt has a key
role among dysregulated pathways in GSCs [19]. Also, the ex-
pression and nuclear localization of β-catenin, and its transcription
factor TCF4, is signiﬁcantly higher in glioma tissue compared to
normal brain tissue, and these ﬁndings also positively correlates to
WHO glioma grade [20]. Moreover, oncogenic activities, such as
proliferation, inhibition of apoptosis and invasion, have also been
associated with Wnt/β-catenin signaling in glioma cell lines
[20,21]. Only a few studies, however, have been performed on
primary- and GSC cultures. Moreover, there are diverging reports
regarding what ligands, receptors and mechanisms are responsible
for Wnt signaling in GBM and GSCs.
GSCs share a number of characteristics and signaling pathways
with ahNSCs [5,19,22]. We have previously identiﬁed the Wnt
pathway as a distinguishing factor between normal and malignant
stem cells from the adult human brain [19]. Here we present a
more extensive analysis of the role of Wnt in GSCs and show that
restoration of Wnt inhibition with the previously identiﬁed can-
didate SFRP1 reduces tumorigenicity through modiﬁcation of p53-
and cell cycle signaling. Together, these ﬁndings suggest that Wnt
plays a pivotal role in GSC malignancy, and that Wnt pathway
inhibition could provide a supplement to current GBM treatment.2. Materials and methods
2.1. Biopsies and cell culturing
Biopsy specimens were obtained from 11 informed and con-
senting patients undergoing surgery for GBM and from seven
patients operated for medically intractable temporal lobe epilepsy.
Tissue harvesting was approved by the Norwegian Regional
Committee for Medical Research Ethics, and histopathological di-
agnosis and grading was performed by a neuropathologist ac-
cording to the WHO classiﬁcation. Biopsies were kept in ice-cold
Leibowitz-15 medium (L-15, Invitrogen) until isolation. Cells were
isolated mechanically and enzymatically with trypsin-EDTA (In-
vitrogen), then blocked using 2 mg/mL human albumin (Octa-
pharma Pharmazeutika Produktionges) and washed in L-15 twice.
The cells were cultured in serum free Dulbecco's Modiﬁed Eagle's
Medium (DMEM; Gibco) containing 10 ng/mL bFGF, 20 ng/mL EGF
(both from R&D Systems) penicillin/streptomycin 100 U/mL of
both (Lonza), heparin 1 ng/mL (Leo Pharma), HEPES 8 mM (Lonza)
and 1:50 B27-supplement (Gibco), as previously described [6]. The
cell culture assays were performed using three primary cell cul-
tures (T2609, T0836 and T1008) between passage two and 10. We
have previously shown that primary GSC cultures treated this waymake invasive tumors upon transplantation [6], and that both
ahNSCs and GSCs self-replicate and can be differentiated into the
different lineages of the CNS [1]. In experiments using re-
combinant human SFRP1 (Sino Biological Inc., Thermo Fisher), the
protein was added in concentrations between 0.8 and 3.2 μg/ml.
2.2. Proliferation assay
Cells were plated at a density of 2000 cells per well in a 96-well
plate for suspension cells (Sarstedt) and cultured for 14 days with
or without recombinant human SFRP1. Proliferation was subse-
quently assessed using Cell Proliferation Kit II XTT (Roche). The
cells were incubated with the XTT solution for 18 h before absor-
bance was analyzed using a microplate reader.
2.3. Sphere formation assay
Cells were plated at a density of 500 cells per well in a 96-well
plate for suspension cells (Sarstedt) and cultured for 14 days with
or without recombinant human SFRP1. Sphere formation was
subsequently counted using an automated colony counter (Gel-
count, Oxford Optronics).
2.4. Apoptosis assay
Cells were plated at a density of 10,000 cells per well in
V-shaped 96-well plates (Sarstedt) and cultured for 48 h with or
without recombinant human SFRP1 (3.2 μg/ml). Apoptosis was
subsequently measured using Cell Death Detection ELISAPLUS
(Roche).
2.5. RNA extraction and quantitative real time PCR
Total RNA was extracted from primary cell cultures at passage
two using Qiazol and the RNeasy Micro Kit (both from Qiagen
GmbH). RNA concentration was determined using a Nanodrop
spectrophotometer (Thermo Fisher) and analyzed for quality using
the Experion System (Bio-Rad). Only samples with an RNA quality
indicator score48.0 were included for further analysis. Quanti-
tative real time PCR (qPCR) was primarily performed using pre-
designed Low Density Array (LDA) cards (Applied Biosystems,
Thermo Fisher), but was also performed individually for certain
genes. The High capacity cDNA Reverse Transcription Kit, TaqMan
Universal PCR Master Mix, TaqMan oligonucleotide primers and
probes and the ABI Prism Detection System and software (all from
Applied Biosystems) were used according to the manufacturer's
instructions. Human β-Actin (TaqMan endogenous control re-
agents, Applied Biosystems) was used as housekeeping gene. The
thermal cycling conditions for both methods were 2 min at 50 °C
and 10 min at 94.5 °C, followed by 40 cycles of 30 s at 97 °C and
1 min at 59.7 °C. The relative gene expression levels were calcu-
lated using the 2δδCT method [23]. For interpretation of the re-
sults, high expression was deﬁned as expressed δCto11 in one or
both groups (GSCs and/or ahNSCs), intermediate expression as δCt
11–15 in one or both groups and low expression/not expressed as
δCt415 in either group.
2.6. Microarray analysis
RNA samples were run in technical triplicates on a HumanHT-
12 chip (Illumina). Analysis and statistics were performed using
J-Express (Molmine). Differential gene analysis was carried out
using RankProd [24]. Enriched pathways were identiﬁed using
Webgestalt (Vanderbilt) and obtained from the Kyoto En-
cyclopedia of Genes and Genomes (KEGG).
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DNA was isolated using GenElute Mammalian Genomic DNA
Miniprep Kit (Sigma-Aldrich). Methylation of the SFRP1 promoter
sequence was analyzed using a SFRP1 speciﬁc probe and the Epi-
Tect Methyl II PCR Assay System, all purchased from SABiosciences
(Qiagen) and used according to the manufacturer's instructions.
2.8. Western blot
Cells were cultured for 10 days with or without recombinant
human SFRP1 (3.2 μg/ml), then washed either in PBS (LONZA) and
homogenized in 10 mmol/L Tris–HCl (pH 7.4), 1% SDS, 10 mmol/L
NaF, and 2 mmol/L Na3VO4 or lysed using Nuclei EZ Prep (Sigma-
Aldrich) for extraction of nuclei. Total protein content was mea-
sured using the BCA Protein Assay Kit (Pierce, Thermo Fisher) and
samples were stored at 70 °C. Thawed aliquots (30 mg of total
protein/aliquot) were mixed with 25% 4XLDS sample buffer (Clear
Page) and 5% mercaptoethanol (Sigma-Aldrich) and boiled for
5 min at 100 °C. The samples were separated on a gradient gel (4–
12% Clear Page SDS gels) and transferred to 0.45 mm PVDF mem-
branes (Amersham) by electroblotting (100 V, 1 h at room tem-
perature). For immunoblotting, the PVDF membranes were ﬁrst
incubated with blocking buffer (5% dry milk (Bio-Rad) in TBS
containing 0.1% Tween-20 (TBST)) for 1 h at room temperature.
The membranes were then washed 35 min with TBST and in-
cubated with primary antibody (mouse anti-active β-catenin (anti-
ABC), 1:1000 from Millipore; Merck KGaA) in blocking buffer
overnight at 4 °C. Next, the membranes were washed 35 min in
TBST and incubated with HRP-conjugated secondary antibody
(Donkey anti-mouse IgG, 1:10,000; Amersham) for 1 h at room
temperature. Finally, membranes were rinsed several times in
wash buffer, incubated with LumiGLO Reserve CL substrate Kit
(KPL) for 1 minute and scanned using the Kodak Image Station
400 MM PRP (Kodak).
2.9. Immunocytochemistry
Spheres were ﬁxed in paraformaldehyde, cryoprotected and
incubated in OCT (Tissue-TEK). Blocks were then cryosectioned at
10 or 20 mm on a freezing microtome, and thawed onto Super
Frost/Plus microscope slides (Menzel-Gläzer). Sections were wa-
shed, blocked and incubated overnight at 4 °C with primary anti-
body: anti-ABC (1:200) from mouse (Millipore) and anti-glial ﬁ-
brillary acidic protein (GFAP; 1:1000) from rabbit (DAKO). Sec-
ondary antibodies were anti-mouse Alexa 488 (donkey, 1:500;
Invitrogen) and anti-rabbit Cy3 (donkey, 1:800; Jackson Labora-
tories). Hoechst 33258 (1:5000; Sigma) was used for nuclear
staining. Analysis and image acquisition was performed on an
Olympus BV 61 FluoView confocal microscope, using the FV10-
ASW 1.7 software (Olympus).
2.10. ELISA analysis of conditioned medium
Cells were plated at a density of 5000 cells per well in a 96-well
plate for suspension cells (Sarstedt). The standard protocol was
used for the GSC cultures, whereas for the ahNSC cultures bFGF
was exchanged with 20 ng/mL TGF-α (R&D systems) and supple-
mented with 1% fetal bovine serum (PAA Laboratories). Quantiﬁ-
cation of SFRP1 protein was performed on technical duplicates
from aspirated culture medium using the ELISA Assay Kit for
SFRP1 (USCN Life Science Inc.).
2.11. Cell cycle analysis
Cells were cultured for 10 days with or without recombinanthuman SFRP1 (3.2 μg/ml). During the last 24 h samples were in-
cubated with EdU (10 μM) from the Click-iT EdU Alexa Fluor 488
Cell Proliferation Assay Kit (Invitrogen). The analysis was assessed
using an LSRII ﬂow cytometer (BD Biosciences) and performed
twice as independent experiments.
2.12. Survival analysis
For the correlation between the Wnt signature expression and
clinical outcome, clinical data was extracted from the Rembrandt
database. Only glioma patients with known clinical information
and gene expression data were included. A Cox proportional ha-
zard regression model was ﬁtted to the data. The variable selection
for this model was performed in a forward, stepwise manner with
Akaike information criterion. From the estimated regression
model, a score was calculated as the exponentiated regression
equation. The patients were divided into two groups based on this
score by hierarchical clustering, these groups were then compared
in a Kaplan–Meier plot and the p-value of the corresponding log
rank test was calculated.
2.13. Statistics
Data are presented as7standard deviations. Differences were
assessed by two-tailed Fisher's exact test and unpaired two-tailed
Student's t-test (Excel, Microsoft Ofﬁce) based on three in-
dependent experiments. Statistical signiﬁcance was determined at
p-values o0.05 (*) and o0.01 (**).3. Results
3.1. Regulation of key Wnt signaling genes in GSCs
Both GSCs from primary GBMs (n¼9) and ahNSCs from tem-
poral lobe resections (n¼3) were cultured as spheres, and upon
transplantation to mice the GSCs formed invasive tumors (data not
shown). Furthermore, both cell types expressed typical stem cell
markers (see Supplementary data). To further explore the role of
Wnt in GBM we performed a qPCR based expressional comparison
of Wnt-related genes. Overall, the similarities were greater than
the differences as most genes, including the gene encoding β-ca-
tenin (CTNNB1), were expressed at the same level in the two cell
types (Fig. 1). However, several important Wnt signaling genes
were differentially regulated. Eight Fzd receptors were highly ex-
pressed in ahNSCs and/or GSCs. Two of these, FZD7 and FZD3, were
signiﬁcantly upregulated in GSCs, eight and 10 times, respectively
(Figs. 1 and 2A). The Wnts were divided into eight intermediately
expressed (Fig. 2B) and three highly expressed genes (Fig. 2C).
Among the highly expressed, two were signiﬁcantly regulated:
WNT5B was 15 times downregulated and WNT7A 67 times upre-
gulated in GSCs (Figs. 1 and 2C). Of the soluble Wnt inhibitors,
three were highly expressed in ahNSCs. Two of these were sig-
niﬁcantly regulated: SFRP4 was 15 times upregulated and SFRP1
was 360 times downregulated in GSCs (Figs. 1 and 2D). We also
examined the expression of nuclear transcription factors and
found that four were highly expressed, among which TCF3 and
LEF1were upregulated in the GSCs, nine and 10 times, respectively
(Figs. 1 and 2E).
3.2. Identiﬁcation of Wnt signature that impacts prognosis
Interestingly, the pattern of upregulation of FZD7, FZD3, SFRP4
and WNT7A, and downregulation of WNT5B and SFRP1, was pre-
sent in all nine tumors, thus constituting a signature of Wnt in-
itiating genes in GSCs (Fig. 3A). To investigate the association
Fig. 1. Pathway map representing the core common Wnt signaling mediators that are highly expressed in ahNSCs and GSCs. Where a gene is signiﬁcantly regulated
(po0.05), green indicates downregulation in GSCs and red indicates upregulated in GSCs. (A) The unstimulated state. (B) The stimulated state.
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tients we examined the impact of these genes on patient survival
(Supplementary Fig. S1). We found that the combined down-
regulation of SFRP1, and upregulation of SFRP4 and FZD7, was as-
sociated with a reduction in median survival from 38.3 months to
17.0 months (po0.00001; Fig. 3B).
3.3. SFRP1 is downregulated through promoter methylation
Wnt signaling consists of an interplay between several distinct
pathways, and the function and relative importance of the in-
dividual pathways in glioma remains largely unknown. With the
exception of WNT3A and WNT5A, it has proved difﬁcult to identify
Wnt ligands or receptors as selective for any part of the Wnt
pathway. Thus, in order to comprehensively manipulate this
pathway we chose to further explore the role of the universal
Wnt-inhibitor SFRP1, the only gene from the signature known to
be capable of blocking all the different Wnt-pathways. We com-
pared its expression in GSCs, ahNSCs and normal brain and found
that it was downregulated in GSCs compared to both ahNSCs and
normal brain tissue (Fig. 4A). To investigate the protein level of
SFRP1 we quantiﬁed SFRP1 protein in cell medium using ELISA
detection. Three ahNSC cultures and four GSC cultures were in-
cubated for seven days and conditioned medium was aspirated
and analyzed. Whereas the ahNSC cultures contained
25.370.4 ng/ml SFRP1, all four GSC cultures were below the de-
tection limit (o0.05 ng/ml; po0.000001; Fig. 4B).Next we performed an analysis of the SFRP1 promoter to in-
vestigate whether downregulation of SFRP1 was caused by epi-
genetic hypermethylation of the promoter. We found that the
SFRP1 promoter was completely unmethylated (o1% methylated)
in all three ahNSC cultures, whereas methylation levels ranged
from 54% to 99% (Fig. 4C) in the four GSCs cultures. As expected,
the degree of methylation was inversely related to SFRP1 expres-
sion (Fig. 4D).
3.4. Treatment with recombinant SFRP1 reduces GSC proliferation
and sphere formation
We treated three primary GSC cultures with recombinant
SFRP1 for 14 days to assess the effect on proliferation and sphere
formation. In all three GSC cultures there was a dose-dependent
decrease in both proliferation and sphere formation upon treat-
ment with SFRP1 (Fig. 5A). Using the highest concentration
(3.2 μg/ml), the reduction in proliferation was 32% for T2609
(po0.001), 54% for T0836 (po0.000001), and 51% for T1008
(po0.000001). The reduction in sphere formation at the highest
concentration was 28% for T2609 (po0.01), 95% for T0836
(po0.000001) and 96% for T1008 (po0.00001; Fig. 5A). In addi-
tion, we also measured the effect of a shorter, 72-h, SFRP1 treat-
ment. This resulted in a more modest, but signiﬁcant, reduction in
proliferation in two of the three GSC cultures (Supplementary Fig.
S2).
The nuclear translocation of β-catenin is a hallmark of Wnt/β-
Fig. 2. Expression of Wnt-related genes in GSCs and ahNSCs. (A) Frizzled receptors. (B) Intermediately expressed Wnts. (C) Highly expressed Wnts. (D) Extracellular Wnt
inhibitors. (E) Transcription factors. * po0.05, ** po0.01.
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way we performed both immunocytochemistry and western blot
of nuclear fractions from cells treated with SFRP1 (3.2 μg/ml) or
control medium for 10 days. The immunocytochemistry analysis
showed both a reduction in the number of cells expressing active
(unphosphorylated) β-catenin (ABC) and an increased expression
of GFAP, a differentiation marker (Fig. 5B). This analysis was sup-
plemented with a western blot revealing a reduction of nuclear
ABC (Fig. 5C) and an increased expression of GFAP in the SFRP1-
treated cells compared to the untreated cells (Supplementary Fig.
S3).
In a therapeutic perspective it is important to know whether
the effect of SFRP1 on growth is permanent or reversible. For this
purpose T0836 was treated with SFRP1 (3.2 μg/ml) or control
medium for 10 days, split back to single cells and replated. Pro-
liferation and sphere formation was then measured every seven
days for three weeks. At all three time points the SFRP1-treatedFig. 3. GSC Wnt signature. (A) Expression of the six genes in nine primary cell cultures. (
regression model combining the genes SFRP1, SFRP4 and FZD7.culture displayed lower cell counts than the control. However, by
the end of the third week the SFRP1-treated culture appeared to
have reestablished exponential growth (Fig. 5D).
3.5. SFRP1 downregulates GSC markers and Wnt target genes
Wnt regulates a variety of cellular processes depending on cell
type and context. To investigate the effect of Wnt inhibition in
GSCs we compared gene expression in T0836 treated with SFRP1
or control medium for 10 days (3.2 μg/ml) by microarray. At 1%
false discovery rate (FDR) the Rank Product algorithm identiﬁed
241 upregulated and 145 downregulated genes. Selected genes
were conﬁrmed by qPCR (Fig. 6A). We have previously identiﬁed
genes that are highly expressed in GSCs and that correlate with
poor clinical outcome [19]. Treatment with SFRP1 led to the
downregulation of three of these genes: Targeting protein for Xklp2
(TPX2) was regulated by 0.53 fold, Kinesin family member 18 AB) Kaplan–Meier curve calculated for two groups deﬁned by the score from the Cox
Fig. 4. Downregulation of SFRP1 through epigenetic silencing. (A) mRNA expression of SFRP1 in ahNSCs, normal brain (NB) and GSCs. (B) Concentration of SFRP1 protein
detected in culture medium from 5000 cells cultured for seven days (ng/ml). (C) Level of SFRP1 promoter methylation in ahNSCs and GSCs. (D) Correlation between SFRP1
mRNA expression and SFRP1 promoter regulation in ahNSCs and GSCs.
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0.74 fold (Fig. 6A). In addition the Wnt target genes Cyclin D2
(CCDN2) and Wnt-inducible signaling protein-1 (WISP1) were
downregulated (0.8 fold and 0.69 fold, respectively), and the Wnt
inhibitor SFRP3 was upregulated by 4.47 fold (Fig. 6A). In addition,
the neural differentiation marker GFAP was conﬁrmed upregulated
by 2.38 fold (Fig. 6A).
3.6. SFRP1 halts cell cycling and induces apoptosis
A signaling pathway enrichment analysis from the list of
SFRP1-regulated genes (5% FDR, fold change 42) revealed a sig-
niﬁcant enrichment of genes related to cell cycle (po0.0001) and
p53 signaling (po0.0001; see Supplementary Data). To investigate
a potential regulation of the cell cycle by SFRP1 we performed a
cell cycle analysis on T0836 treated with SFRP1 or control medium
for 10 days. The analysis showed that treatment with SFRP1 re-
duced the number of cells undergoing cell division from 40% to
12% (Fig. 6C). Furthermore, the fraction of SFRP1-treated cells in
G2 phase was reduced from 28% to 7%, combined with an increase
in the S-phase fraction from 15% to 26%, suggesting that Wnt in-
hibition results in a S/G2 transition arrest (data not shown).
p53 is a tumor suppressor involved in cell cycle arrest, as well
as induction of apoptosis. To test whether SFRP1 induces apoptosis
in GSCs, the same GSC cultures were treated with SFRP1 (3.2 μg/
ml) for 48 h. In all three GSC cultures SFRP1 treatment increasedapoptosis compared to control, with a signiﬁcant increase of 54%
in T0836 (po0.001) and 42% in T2609 (po0.01; Fig. 6B). To in-
vestigate the underlying mechanisms for SFRP1-induced apopto-
sis, we further investigated protein levels of p53, but did not ﬁnd
any regulation of p53 on the protein level, neither for total protein,
nor for the phosphovariants Ser15, Ser20, Ser37 and Ser315
(Supplementary Fig. S3). However, using qPCR we found that two
important p53 target genes were upregulated Growth arrest and
DNA-damage-inducible protein 45 alpha (GADD45A) by 2.19 fold,
Cyclin-Dependent Kinase Inhibitor 1 A (CDKN1A, also called p21) by
2.90 fold, whereas B-Cell Translocation Gene 2 (BTG2) was un-
changed, and BAX was downregulated by 0.15 fold (Fig. 6A).4. Discussion
This study is the ﬁrst comprehensive investigation of the role of
Wnt in CSCs from GBM. By comparing primary GSC- and ahNSC
cultures we have identiﬁed a Wnt activation signature of six genes
involved in Wnt signaling at the cell surface. The combined ex-
pression of three of these genes (FZD7, SFRP1 and SFRP4) was
correlated with clinical outcome in patients with malignant glio-
ma. Furthermore, we demonstrated that treatment with the
downregulated inhibitor SFRP1 reduced proliferation and sphere
formation through regulation of cell cycle and apoptosis.
This study is based upon in vitro exploration of early passage
Fig. 5. Treatment with SFRP1 impedes growth through inhibition of Wnt/β-catenin. (A) Proliferation (upper panel) and sphere formation (lower panel) of cells treated with
SFRP1 or control medium. Concentrations in μg/ml and results are presented as mean7SD. (B) Immunocytochemistry of GSC spheres (T1008) showing the expression of
active (unphosphorylated) β-catenin (green) and GFAP (red) in non-treated GSCs (upper panel) and SFRP1-treated GSCs (3.2 μg/ml; lower panel). Cell nuclei stained with
Hoechst (blue). Scale bar is 20 μm. (C) Western blot of active (unphosphorylated) β-catenin in three primary glioma cultures treated with SFRP1 (3.2 μg/ml) or medium for 10
days. (D) T0836 was treated with SFRP1 (3.2 μg/ml) or medium for 10 days, then replated and cultured for three weeks. The graph shows proliferation and sphere formation
of SFRP1-treated cells compared to control after treatment withdrawal. * po0.05, ** po0.01.
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conditions have been demonstrated to maintain tumorigenicity,
genotype and the patient speciﬁc characters of individual tumors
[6,25,26]. As a result the ﬁndings presented in this paper are likely
to represent biological mechanisms that are important for at least
a subset of GBMs. However, as the work is based on in vitro stu-
dies, the importance of Wnt signaling in GBM needs further stu-
dies in an in vivo setting. Since the stability and availability of
SFRP1 is limited, we have not performed such studies currently.
The microarray-based pathway enrichment analysis of signal-
ing pathways revealed a signiﬁcant regulation of two pathways
upon Wnt inhibition: cell cycle and p53 signaling. Through func-
tional analysis we were able demonstrate that SFRP1 halts cell
cycling and induces apoptosis. p53 is a tumor suppressor involved
in both cell cycle arrest and apoptosis. We did not identify reg-
ulation of p53 at the protein level, although two important target
genes, GADD45A and CDKN1A (p21), were upregulated upon SFRP1
treatment.
In addition to regulating a range of embryonic processes, the
Wnt signaling pathway is a regulator of somatic stem cells. In
hematopoietic stem cells, Wnt is a promoter of self-renewal [27],
and in human embryonic stem cells (ESCs) the Wnt receptor FZD7
is essential for maintenance of the undifferentiated, pluripotent
state [28]. The Wnt inhibitor SFRP1 may have the opposite effect,
promoting ESC differentiation into neural progenitors [29]. Con-
versely, a reduction in SFRP1 expression enables mammary epi-
thelial cell lines to acquire a CD44high/CD24low expression pattern
associated with both mammary and breast cancer stem cells [30],
indicating a close relationship between Wnt, stemness and ma-
lignancy. Interestingly, FZD7 and SFRP1 were among the three
genes we found to be correlated with clinical outcome in glioma
patients.
This study provides further evidence of the importance Wntsignaling in GBM and GSCs. The expression and nuclear localiza-
tion of β-catenin has been shown to correlate with glioma grade,
and high expression is predictive of poor prognostic outcome in
patient tumor biopsies [31–33]. We here present data showing
that Wnt plays an important role in GSC proliferation and apop-
tosis in vitro. This is in line with studies performed on cell lines
that have shown that Wnt/β-catenin signaling is implicated in
oncogenic activities, such as proliferation, inhibition of apoptosis
and invasion [20,21]. The upregulation of transcription factors TCF/
LEF are also in line with previous ﬁndings [20,34].
The Wnt inhibitor SFRP1 is a well-established tumor sup-
pressor in a number of cancers, where it is commonly silenced
epigenetically through hypermethylation of the promoter region
[35]. Hypermethylation of the SFRP1 promoter has previously been
described in glioma cell tissue [16]. We also found this to be the
case in GSCs. Loss of SFRP1 expression in normal cells has been
shown to induce a CSC phenotype [30], and in cancer it is an in-
dependent predictor of advanced disease and unfavorable clinical
outcome [36–38]. Recent experimental studies indicate that the
tumor suppressor effect of SFRP1 includes apoptosis [39] and se-
nescence in [40], which is largely consistent with the ﬁndings in
this paper.
In contrast to SFRP1, SFRP4 was upregulated in GSCs. Upregu-
lation of SFRP4 was also associated with an unfavorable clinical
prognosis, indicating that SFRP4 may initiate Wnt signaling in
GSCs. Such a Wnt-agonistic SFRP4 effect has previously been ob-
served in colorectal cancer cells [41,42]. In fact, SFRP1 and SFRP4
belong to different SFRP subgroups based on sequence homology
and antagonize one another's activity [14,43]. Interestingly, a re-
cent study found that SFRP4 increased the chemotherapeutic re-
sponse in glioma cell lines [44]. More studies are thus needed in
order to understand the role of SFRP4 in glioma.
Fig. 6. SFRP1 regulates cell cycle and apoptotic pathways. (A) Microarray analysis of SFRP1-treated cells reveals regulation of cell cycle and p53 pathways. Selected genes
were conﬁrmed through qPCR. (B) Measurement of apoptosis in three GSC cultures after 48 h of treatment with SFRP1 of medium. (C) Cell cycle analysis showing a reduction
in the number of proliferating cells. * po0.05, ** po0.01.
K.S. Kierulf-Vieira et al. / Experimental Cell Research 340 (2016) 53–61605. Conclusion
Wnt signaling activation through regulation of receptors, li-
gands and inhibitors appears to be important in GBM stem cell
maintenance, and thus tumor propagation. As we have showed
that reestablishment of SFRP1 signaling is effective but reversible,
further therapeutic strategies should explore the possibilities of
non-reversible targeting of this Wnt signaling interaction.Funding
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